Lens Wearing Experience and Biocompatibility of a Multi-Purpose Disinfecting Solution (MPDS)
1 other identifier
interventional
125
1 country
1
Brief Summary
The purpose of this study was to evaluate the efficacy of a new multipurpose disinfecting solution in silicone hydrogel and soft contact lens wearers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable healthy
Started Jun 2011
Shorter than P25 for not_applicable healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2011
CompletedFirst Submitted
Initial submission to the registry
November 18, 2011
CompletedFirst Posted
Study publicly available on registry
November 22, 2011
CompletedResults Posted
Study results publicly available
November 19, 2012
CompletedNovember 19, 2012
November 1, 2012
4 months
November 18, 2011
October 19, 2012
November 16, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Corneal Fluorescein Staining Type at Baseline
Corneal staining type was assessed by the investigator for each of 5 regions of the cornea, i.e., four quadrants plus central. The investigator instilled fluorescein dye and examined the cornea with a slit lamp, i.e., biomicroscope and a yellow filter. Corneal staining type was recorded on a 5-point scale for each region: 0-none; 1-micropunctate; 2-macropunctate; 3-coalesced macropunctate; 4-patch (\>/= 1mm). The five regions were summed, for a maximum score of 20. A lower score represents a more desirable outcome.
Day 0 (Baseline)
Corneal Fluorescein Staining Type at Day 30
Corneal staining type was assessed by the investigator for each of 5 regions of the cornea, i.e., four quadrants plus central. The investigator instilled fluorescein dye and examined the cornea with a slit lamp, i.e., biomicroscope and a yellow filter. Corneal staining type was recorded on a 5-point scale for each region: 0-none; 1-micropunctate; 2-macropunctate; 3-coalesced macropunctate; 4-patch (\>/= 1mm). The five regions were summed, for a maximum score of 20. A lower score represents a more desirable outcome.
Day 30
Corneal Fluorescein Staining Area at Baseline
Corneal staining was assessed by the investigator for each of five regions of the cornea, i.e., four quadrants plus central. The investigator instilled fluorescein dye and examined the cornea with a slit lamp, i.e., biomicroscope and a yellow filter. The area (extent) of corneal staining for each of the five areas was estimated \[i.e., 0% (no staining in the region) to 100% (staining covers entire region)\], for a maximum score of 100% per eye. A lower score represents a more desirable outcome.
Day 0 (Baseline)
Corneal Fluorescein Staining Area at Day 30
Corneal staining was assessed by the investigator for each of five regions of the cornea, i.e., four quadrants plus central. The investigator instilled fluorescein dye and examined the cornea with a slit lamp, i.e., biomicroscope and a yellow filter. The area (extent) of corneal staining for each of the five areas was estimated \[i.e., 0% (no staining in the region) to 100% (staining covers entire region)\], for a maximum score of 100% per eye. A lower score represents a more desirable outcome.
Day 30
Study Arms (1)
OPTI-FREE PureMoist
EXPERIMENTALOPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days
Interventions
FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
Eligibility Criteria
You may qualify if:
- Wear silicone hydrogel or traditional soft contact lenses on a daily wear basis, (a minimum of 8 hours per day) for at least one month prior to Visit 1;
- Habitual use of a multi-purpose solution containing PHMB for at least 30 days prior to Visit 1;
- Vision correctable to 20/30 (Snellen) or better in each eye at distance with pre-study lenses at Visit 1;
- Read, sign, and date IRB-approved informed consent and privacy document;
- Be generally healthy and have normal ocular health;
- Willing to follow the study procedures and visit schedule;
You may not qualify if:
- Wear lenses on an extended wear basis during the study;
- Known sensitivity or intolerance to PHMB, POLYQUAD, or ALDOX preserved lens care products;
- Monocular subject;
- Requirestoric or multifocal contact lenses;
- Use of additional lens care products other than a PHMB multi-purpose solution such as daily or enzyme cleaners within the one week prior to Visit 1;
- Use of topical ocular over-the-counter (OTC) or prescribed topical ocular medications, with the exception of rewetting drops, within 7 days prior to Visit 1;
- Any abnormal ocular condition observed during the Visit 1 Slit-lamp examination;
- Ocular surgery within the 12 months prior to Visit 1;
- Use of any systemic medication which has known or expected ocular or systemic side effects at Visit 1, that in the clinical judgment of the investigator, could affect the subject's participation in this study;
- Any systemic disease at Visit 1 that may affect the eye or be exacerabated by use of contact lenses or contact lens solutions or which could prevent subjects from wearing their lenses at least 8 hours per day;
- Participation in any clinical study within 30 days of Visit 1;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Alcon Researchlead
Study Sites (1)
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, 76314, United States
Results Point of Contact
- Title
- Jami Kern, Ph.D.
- Organization
- alcon Blobal Medical Affairs
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 18, 2011
First Posted
November 22, 2011
Study Start
June 1, 2011
Primary Completion
October 1, 2011
Study Completion
October 1, 2011
Last Updated
November 19, 2012
Results First Posted
November 19, 2012
Record last verified: 2012-11